Our results are further supported by similar lapatinib-focused analyses of ER and BCL-2 co-expression [17], which demonstrated parallel upregulation of ER and BCL-2 within two pre-clinical models of treatment resistant HER2+ breast cancer as well as a subset of lapatinib-treated HER2+ clinical samples. This evidence concerns the gene ERBB2 and breast carcinoma.